TNFRSF10B and chondrosarcoma: Another agent known as INBRX-109, a humanized tetravalent antibody targeting DR5, is being studied in a randomized, placebo-controlled phase 2 study in patients with unresectable and/or metastatic conventional chondrosarcoma (ClinicalTrials.gov Identifier: NCT04950075).